Response to "Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test?"

A Tornio, A M Filppula, O Kailari, M Neuvonen, T H Nyrönen, T Tapaninen, P J Neuvonen, M Niemi, J T Backman, Glucuronidation Converts Clopidogrel to a Strong Time‐Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions Clinical Pharmacology & Therapeutics. ,vol. 96, pp. 498- 507 ,(2014) , 10.1038/CLPT.2014.141

M Shebley, W Fu, P Badri, DAJ Bow, V Fischer, Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir Clinical Pharmacology & Therapeutics. ,vol. 102, pp. 679- 687 ,(2017) , 10.1002/CPT.689

Mikko Niemi, Janne T. Backman, Matti K. Itkonen, Aleksi Tornio, Outi Lapatto‐Reiniluoto, Mikko Neuvonen, Pertti J. Neuvonen, Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. Clinical Pharmacology & Therapeutics. ,vol. 105, pp. 219- 228 ,(2019) , 10.1002/CPT.1099

Mohamad Shebley, Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test? Clinical Pharmacology & Therapeutics. ,vol. 105, pp. 320- 321 ,(2019) , 10.1002/CPT.1196

Ezra A. Amsterdam, Nanette K. Wenger, Ralph G. Brindis, Donald E. Casey, Theodore G. Ganiats, David R. Holmes, Allan S. Jaffe, Hani Jneid, Rosemary F. Kelly, Michael C. Kontos, Glenn N. Levine, Philip R. Liebson, Debabrata Mukherjee, Eric D. Peterson, Marc S. Sabatine, Richard W. Smalling, Susan J. Zieman, 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes Journal of the American College of Cardiology. ,vol. 64, pp. e139- e228 ,(2014) , 10.1016/J.JACC.2014.09.017